Innovative Therapeutic Approaches for Huntington's Disease: From Nucleic Acids to GPCR-Targeting Small Molecules

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Huntington's disease (HD) is a fatal neurodegenerative disorder caused by expanded CAG repeats in the huntingtin gene, leading to toxic mutant huntingtin (mHTT).
• Current therapeutic strategies for HD primarily focus on lowering mHTT levels, with nucleic acid-based approaches like small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) showing potential.
• However, delivering these nucleic acid therapies to the central nervous system (CNS) presents significant challenges, often requiring invasive direct injections.

Purpose of the Study:

• To review current huntingtin-lowering strategies for HD, including ongoing clinical trials.
• To introduce and evaluate an innovative therapeutic approach targeting the G protein-coupled receptor GPR52 for HD treatment.
• To explore the potential of GPR52 antagonists as a novel therapeutic strategy for Huntington's disease.

Main Methods:

• Review of existing literature on huntingtin-lowering strategies and clinical trials for HD.
• Identification and characterization of GPR52 as a potential therapeutic target for HD.
• High-throughput screening and structure-activity relationship studies to discover potent and selective GPR52 antagonists.
• Assessment of GPR52 antagonists in preclinical HD models (HD mice) to evaluate their efficacy in reducing mHTT and ameliorating disease phenotypes.

Main Results:

• Nucleic acid-based strategies for lowering mHTT face considerable drug delivery challenges to the CNS.
• GPR52, a striatal-enriched orphan GPCR, has been identified as a promising therapeutic target for HD.
• Discovery of chemically simple, potent, and selective GPR52 antagonists.
• These antagonists effectively reduce both soluble and aggregated mHTT in the striatum of HD mice.
• GPR52 antagonists ameliorate HD-like behavioral and pathological defects in preclinical models.

Conclusions:

• GPR52 antagonists represent a promising novel therapeutic strategy for Huntington's disease, offering an alternative to challenging nucleic acid delivery methods.
• Inhibition of GPR52 demonstrates efficacy in reducing mutant huntingtin and improving HD-related symptoms in preclinical studies.
• This small molecule approach holds potential for deterring HD progression and offers a significant advantage over current delivery-limited strategies.